Suneel Kamath, MD, discusses the current challenges of treating patients with cholangiocarcinoma, the need for more tolerable therapies in this population, and how the significant ORRs and impressive safety profile seen so far with RLY-4008 in the ReFocus trial are indicative of this agent’s efficacy and durability in FGFR2-rearranged cholangiocarcinoma.
Press Release
Mirvetuximab soravtansine has been granted accelerated approval by the U.S. Food and Drug Administration on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.
The FDA has extended the Prescription Drug User Fee Act goal date to May 1, 2023, for the biologics license application seeking the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.
Patients with localized pancreatic adenocarcinoma who received care at a multidisciplinary clinic had significantly higher neoadjuvant therapy completion rates than those treated at a specialty-specific clinic.
Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.
The score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–small cell lung cancer treated with single-agent immunotherapy, regardless of performance status.
Investigators hope to add an additional therapeutic option to the treatment paradigm of non–small cell lung cancer with the development of the novel agent eftilagimod alpha.
Press Release
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that a protein complex that governs gene expression sometimes gets rewired during breast cancer to help estrogen receptor positive tumors resist endocrine therapies and become more aggressive.
GlaxoSmithKline plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies.
The European Commission has approved cemiplimab-rwlc monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy.
The combination of pembrolizumab and physician’s choice of chemotherapy produced a statistically significant overall survival benefit vs chemotherapy plus placebo in patients with HER2-negative, locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.
In combination with standard-of-care carboplatin and pemetrexed, the investigational agent LP-300 will be evaluated in never smokers with non–small cell lung cancer in the phase 2 HARMONIC study.
Daniel J. George, MD, discusses the clinical implications use of key trials in metastatic castration-resistant prostate cancer.
The oral PI3Kδ inhibitor zandelisib produced an overall response rate in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström macroglobulinemia.
The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.
Press Release
Two new studies show how bugs could help tumors progress and resist treatment.
The FDA has accepted and granted priority review to a biologics license application seeking the apporoval of epcoritamab in patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.
After receiving FDA feedback regarding supplemental assay validation information and comparability data for lifileucel in advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application submission during the first quarter of 2023.
The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.
Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.
The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).
OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.
The European Commission has approved zanubrutinib for the treatment of adult patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia.
Camsirubicin in combination with pegfilgrastim produced encouraging clinical activity and safety in patients with advanced soft tissue sarcoma.
The FDA has asked Clovis Oncology to limit use of rucaparib to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.
Autologous tumor lysate-loaded dendritic cell vaccination used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma as well as those with recurrent disease.
Improved mantle cell lymphoma treatments are necessary for patients who have relapsed on or are refractory to BTK inhibitors, according to findings from SCHOLAR-2, a multicenter, retrospective chart review of European patients with MCL who relapsed following or were intolerant to BTK inhibitors.
Ponatinib plus reduced-intensity chemotherapy produced a higher rate of minimal residual disease–negative complete remission compared with imatinib in patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
